Search Results
Oct 09, 2025, 06:00 ET Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
experimental burden, the platform also provides mechanistic insights that enhance clinical translatability, modeling not only cell survival but also changes in gene expression, to understand why cells respond or resist treatment. "By implementing a lab-in-the-loop approach, we can move beyond
More news about: Turbine
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its
More news about: ARTHEx Biotech
Oct 08, 2025, 17:31 ET Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight
CRISPR-Cas9 gene editing is a revolutionary genome-editing technology that enables precise and targeted changes to DNA within living cells. Intellia Therapeutics' Nexiguran Ziclumeran is an investigational, in vivo CRISPR-Cas9 gene-editing therapy designed to treat hereditary
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 16:25 ET Le brevet européen sur la technologie des plasmides de virus adénoassociés EpyQ® d'Ascend Advanced Therapies défendu avec succès auprès de l'Office européen des brevets (OEB)
Maryland, 8 octobre 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), partenaire de développement du niveau du gène au niveau conforme aux bonnes pratiques de fabrication, a annoncé aujourd'hui que son brevet européen EP3722434 protégeant EpyQ®, la technologie exclusive
More news about: Ascend Advanced Therapies (Ascend)
Oct 08, 2025, 14:28 ET Une étude de l'IIT Madras, l'institut n° 1 de l'Inde, et d'une université danoise révèle des « interrupteurs » génétiques susceptibles de transformer la recherche sur les maladies
variantes génétiques de la levure travaillent ensemble pour activer des voies métaboliques précédemment dormantes. En révélant comment ces interactions gène-gène recâblent dynamiquement le métabolisme, l'étude fournit un cadre puissant pour décoder les associations de multiples gènes et modifier et améliorer
More news about: IIT Madras
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
significant progress with the FDA regarding its LX2006 gene therapy for Friedreich ataxia cardiomyopathy, with the agency indicating openness to pooling Phase I/II data with pivotal study data to support an accelerated
More news about: Equity Insider
Oct 08, 2025, 09:31 ET India's No: 1 Ranked Institute, IIT Madras & Danish University Study reveals Genetic 'Switches' that can transform Disease Research
multi-omic approaches, showed how genetic variants in yeast work together to activate previously dormant metabolic pathways. By revealing how these gene–gene interactions dynamically rewire metabolism, the study provides a powerful framework for decoding how multiple genes combine to modify and improve
More news about: IIT Madras
Oct 08, 2025, 09:26 ET India's No: 1 Ranked Institute, IIT Madras & Danish University Study reveals Genetic 'Switches' that can transform Disease Research
multi-omic approaches, showed how genetic variants in yeast work together to activate previously dormant metabolic pathways. By revealing how these gene–gene interactions dynamically rewire metabolism, the study provides a powerful framework for decoding how multiple genes combine to modify and improve
More news about: IIT Madras
Oct 08, 2025, 09:00 ET European Patent on Ascend Advanced Therapies' EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
advancing gene therapy development with confidence in the IP landscape." The successful maintenance of this patent provides a strong foundation for the continued development and application of EpyQ® technology in the rapidly evolving field of gene therapy.
More news about: Ascend Advanced Therapies (Ascend)
Oct 08, 2025, 08:58 ET Trial-and-Error Medicine Is Dead: New Book Shows Genomics and AI Are Already Saving Lives
Wearables: Consumer sensors as prevention and behavior-change tools. Genomics: Drug-gene testing that prevents life-threatening reactions and wasted spending. Big Data + AI: Predictive analytics that spot risks
More news about: James Wallace
Oct 08, 2025, 08:30 ET ImmunoVec Launches from Stealth with up to $40.7 Million ARPA-H EMBODY Award to Advance In Vivo Cell Engineering Platform for Autoimmune Diseases
a pipeline of cell type-specific gene therapies for multiple, potentially fatal pediatric immune diseases, such as X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome and IPEX syndrome. Pre-clinical data demonstrate that these therapies restore normal gene expression and have the potential
More news about: ImmunoVec
Oct 08, 2025, 08:00 ET Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
Preclinical small molecule offers a novel approach for tumors characterized by high interferon-stimulated gene (ISG) expression LEXINGTON, Mass.,
More news about: Accent Therapeutics
Oct 08, 2025, 03:00 ET Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and preliminary efficacy of
More news about: Complement Therapeutics
Oct 08, 2025, 02:30 ET Enzene First in India for Virtuosi®
contains 100 hours of content and 26 virtual reality segments to solidify your employees' learning in aseptic processing, microbiology and cell & gene therapy. As a global provider, Virtuosi is available in 7 different languages and can be adapted to meet your needs locally. For
More news about: Quality Executive Partners, Inc.
Oct 08, 2025, 02:30 ET Enzene First in India for Virtuosi®
contains 100 hours of content and 26 virtual reality segments to solidify your employees' learning in aseptic processing, microbiology and cell & gene therapy. As a global provider, Virtuosi is available in 7 different languages and can be adapted to meet your needs locally. For
More news about: Quality Executive Partners, Inc.
Oct 07, 2025, 18:20 ET Klotho Neurosciences Announces Expiration of Letter of Intent
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Oct 07, 2025, 17:31 ET AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight
Elements (XREs) in DNA to trigger the expression of specific target genes. Additionally, AHR interacts with other transcription factors, influencing wider gene networks. This pathway is significant for regulating cytochrome P450 enzymes, such as CYP1A1 and CYP1A2, which are vital for
More news about: DelveInsight Business Research, LLP
Oct 07, 2025, 11:36 ET Crunch Lab Raises $5M to Build the Intelligence Layer for Decentralized AI
asset pricing predictions. Broad Institute of MIT and Harvard: Breakthrough results in cancer gene research using computer vision. FX OTC: Live deployment of Mid+One, a crowdsourced mid-market
More news about: Crunch Lab
Oct 07, 2025, 11:20 ET Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
Gene Therapies dominated with US$ 4.6 billion in 2024. Novartis' Zolgensma® for SMA and Sarepta's gene therapies for Duchenne muscular dystrophy highlight the transformative role of single-dose, potentially curative treatments. By 2033, gene therapies are expected to
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 11:00 ET Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
Gene Therapy, valued at US$ 28 billion in 2024, is the fastest-growing segment. Recent FDA approvals and ongoing clinical trials for Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and sickle cell disease (SCD) are redefining treatment paradigms. By 2033, gene therapies
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 10:05 ET Peli BioThermal Announces Acquisition to Expand Cold Chain Logistics Solutions and Advance Cryogenic Cell and Gene Therapy Transport
portfolio includes cryogenic shippers and the evoIS® technology platform, designed to meet the rigorous demands of the rapidly growing Cell and Gene Therapy (C>) sector.
More news about: Peli BioThermal
Oct 07, 2025, 10:05 ET Peli BioThermal Announces Acquisition to Expand Cold Chain Logistics Solutions and Advance Cryogenic Cell and Gene Therapy Transport
portfolio includes cryogenic shippers and the evoIS® technology platform, designed to meet the rigorous demands of the rapidly growing Cell and Gene Therapy (C>) sector.
More news about: Peli BioThermal
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapies targeting hematologic and genetic diseases, ex vivo HSC gene therapies for genetic disorders, and angiogenesis for ischemic diseases.
More news about: Celaid Therapeutics Inc.
Oct 07, 2025, 09:00 ET Precision NeuroMed Granted FDA Orphan Drug Designation by U.S. FDA for Treatment of Glioblastoma Multiforme (GBM)
convection-enhanced delivery (CED) to bypass the BBB and enable direct, targeted administration of nanoparticles, including proteins, liposomes, and gene therapy at therapeutic concentrations to the brain. "Receiving Orphan Drug Designation is an important milestone for Precision
More news about: Precision NeuroMed
Oct 07, 2025, 08:34 ET GeneVentiv Therapeutics Selected into NHLBI Catalyze Program to Fund IND-Enabling Toxicology Study for GENV-HEM
Therapeutics. "It removes a significant cost barrier in gene therapy development and directs investor capital to higher-return activities to advance GENV-HEM into the clinic. This also frees capital for further development of GENV-002, our gene editing therapy for both Infantile and Late Onset Pompe
More news about: GeneVentiv Therapeutics